



Spruce Biosciences Announces Acceptance of Abstract for Presentation at the Annual Meeting of the Endocrine Society (ENDO 2023)

June 12, 2023

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jun. 12, 2023-- [Spruce Biosciences, Inc.](#) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that a submitted abstract was accepted for the [105th Annual Meeting of the Endocrine Society \(ENDO 2023\)](#) taking place June 15-18, 2023, in Chicago. In a poster presentation, the company will highlight the effect of tildacerfont on gonadotropins and testicular steroidogenesis in men with classic congenital adrenal hyperplasia (CAH).

ENDO 2023 presentation details are as follows:

Title: [Effect of tildacerfont on gonadotropins and testicular steroidogenesis in men with classic 21-hydroxylase deficiency](#)

Session Title: P72 – Clinical Adrenal and Pituitary: Adrenal Insufficiency

Session Date & Time: 1:00 p.m. – 2:00 p.m. CT on June 17, 2023

Presenter: Will Charlton, M.D., M.A.S., Chief Medical Officer, Spruce Biosciences

Authors: Ahmed Khattab, M.D., Will Charlton, M.D., M.A.S., and Richard Auchus, M.D., Ph.D.

The poster will be available on the [company's website](#), beginning June 17, 2023, at 2:00 p.m. CT. Access more information about ENDO 2023 [here](#).

About Spruce Biosciences

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). Spruce is also developing tildacerfont for women suffering from polycystic ovary syndrome (PCOS) with primary adrenal androgen excess. To learn more, visit www.sprucebiosciences.com and follow us on Twitter @[Spruce_Bio](#), [LinkedIn](#), [Facebook](#) and [YouTube](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20230612005110/en/): <https://www.businesswire.com/news/home/20230612005110/en/>

Media

Will Zasadny

Evoke Canale

(619) 961-8848

will.zasadny@evokecanale.com

media@sprucebio.com

Investors

Xuan Yang

Solebury Strategic Communications

(415) 971-9412

xyang@soleburystrat.com

investors@sprucebio.com

Source: Spruce Biosciences, Inc.